<DOC>
	<DOCNO>NCT01309282</DOCNO>
	<brief_summary>This observational study ass long-term efficacy safety MabThera/Rituxan routine clinical practice patient sero-positive rheumatoid arthritis non-responders intolerant single tumour necrosis factor ( TNF ) inhibitor . Data collect patient 2 year .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders Intolerant Single TNF-Inhibitor ( PORTSMAB )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Rheumatoid arthritis positive rheumatoid factor and/or antiCCP Nonresponder intolerant single TNFinhibitor therapy Initiating treatment MabThera/Rituxan Contraindications MabThera/Rituxan therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>